NasdaqGS:TEMLife Sciences
Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform
Tempus AI (TEM) is back in focus after publishing a JCO Precision Oncology study showing its advanced comprehensive genomic profiling tools identified actionable cancer treatment options that standard in network tests missed for about 12% of patients.
See our latest analysis for Tempus AI.
The study arrives after a busy few weeks, with Tempus AI striking an expanded multi year collaboration with Merck and a new alliance with NYU Langone Health. Yet the share price has seen a 29.85% 90 day...